Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Lantern Pharma, Inc. (LTRN)

NASDAQ:LTRN

LTRN

Lantern Pharma

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding LTRN?

Track your performance easily

Link Broker

Lantern Pharma (LTRN) Stock Price & Analysis

241 Followers

LTRN Stock Chart & Stats

Advanced Chart >

Day’s Range$0 - $0

52-Week Range$2.79 - $11.99

Previous Close$3.08

Volume108.47K

Average Volume (3M)45.36K

Market Cap

$33.22M

Enterprise Value$5.45M

Total Cash (Recent Filing)$28.05M

Total Debt (Recent Filing)$291.24K

Price to Earnings (P/E)―

Beta2.23

Next Earnings

Mar 06, 2025

EPS Estimate

-$0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.77

Shares Outstanding10,784,725

10 Day Avg. Volume58,590

30 Day Avg. Volume45,358

Standard Deviation0.21

R-Squared0.13

Alpha-0.03

Financial Highlights & Ratios

Price to Book (P/B)1.19

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)-1.50

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit10.00T>

Enterprise Value/Ebitda-0.66

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Lantern Pharma News

PremiumThe Fly

Lantern Pharma doses first patient in LP-300 trial expansion cohort

5d ago

LTRN

PremiumThe Fly

Lantern Pharma reports Q3 EPS (42c), one estimate (56c)

16d ago

LTRN

PremiumCompany Announcements

Lantern Pharma Discusses Q3 Financial Results Webinar

16d ago

LTRN

PremiumCompany Announcements

Lantern Pharma Advances AI-Driven Cancer Therapies

16d ago

LTRN

PremiumThe Fly

Lantern Pharma granted fast track designation for LP-184

1M ago

LTRN

PremiumCompany Announcements

Lantern Pharma Q2 Results and LP-300 Clinical Trial Update

4M ago

LTRN

PremiumThe Fly

Lantern Pharma reports Q2 EPS (46c), one estimate (55c)

4M ago

LTRN

PremiumThe Fly

Lantern Pharma highlights ‘promising’ prelinical results of LP-184

4M ago

LTRN

See More LTRN News >

Financials

Annual

Income Statement >

Ownership Overview

22.88% Insiders

4.17% Mutual Funds

3.64% Other Institutional Investors

65.55% Public Companies and

Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Detailed Risk Analysis >

LTRN FAQ

What was Lantern Pharma, Inc.’s price range in the past 12 months?

Lantern Pharma, Inc. lowest stock price was $2.79 and its highest was $11.99 in the past 12 months.

What is Lantern Pharma, Inc.’s market cap?

Currently, no data Available

When is Lantern Pharma, Inc.’s upcoming earnings report date?

Lantern Pharma, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 102 days.

How were Lantern Pharma, Inc.’s earnings last quarter?

Lantern Pharma, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.14.

Is Lantern Pharma, Inc. overvalued?

According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lantern Pharma, Inc. pay dividends?

Lantern Pharma, Inc. does not currently pay dividends.

What is Lantern Pharma, Inc.’s EPS estimate?

Lantern Pharma, Inc.’s EPS estimate is -$0.51.

How many shares outstanding does Lantern Pharma, Inc. have?

Lantern Pharma, Inc. has 10,784,725 shares outstanding.

What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?

Lantern Pharma, Inc. reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 12.281%.

Which hedge fund is a major shareholder of Lantern Pharma, Inc.?

Among the largest hedge funds holding Lantern Pharma, Inc.’s share is Fisher Asset Management LLC. It holds Lantern Pharma, Inc.’s shares valued at N/A.

---

Lantern Pharma Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-53.03%

Trailing 12-Months

Asset Growth

-36.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lantern Pharma, Inc.

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.

---

LTRN Company Deck

---

LTRN Earnings Call

Q3 2024

0:00 / 0:00

---

LTRN Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Feb<br/>2024","9":"May<br/>2024","12":"Aug<br/>2024","25":"Aug<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,3.4523076923076923,3.164615384615385,2.8769230769230774,2.5892307692307694,2.3015384615384615,2.013846153846154,1.7261538461538466,1.4384615384615387,1.1507692307692308,0.8630769230769233,0.5753846153846158,0.2876923076923079,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,3.4523076923076923,3.164615384615385,2.8769230769230774,2.5892307692307694,2.3015384615384615,2.013846153846154,1.7261538461538466,1.4384615384615387,1.1507692307692308,0.8630769230769233,0.5753846153846158,0.2876923076923079,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.74,3.4523076923076923,3.164615384615385,2.8769230769230774,2.5892307692307694,2.3015384615384615,2.013846153846154,1.7261538461538466,1.4384615384615387,1.1507692307692308,0.8630769230769233,0.5753846153846158,0.2876923076923079,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.66,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.28,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.56,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.03,"date":1700179200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.65,"date":1711065600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >